Johnson and Johnson Newswire

Comprehensive Real-Time News Feed for Johnson and Johnson.

Results 1 - 20 of 1,963 in Johnson and Johnson

  1. Cancer society to hold Driven to Quit challenge in 2015Read the original story w/Photo

    1 hr ago | InsideHalton.com

    Many smokers feel they get nagged to quit. On top of everything else, they're dealing with an addiction, something that's causing their brain to actively work against them.

    Comment?

  2. Carlyle Inks Deal in Each Major Continent to End Year as BusiestRead the original story

    Yesterday | Bloomberg

    After the founders of Carlyle Group LP took a break last week to circulate a Dr. Dre-inspired holiday rap video , they got back to what they do best. The private equity firm struck three deals in two days, cementing its status as the busiest buyout firm this year.

    Comment?

  3. Have Several Niche Markets? Choose the Right Blog Strategy.Read the original story w/Photo

    Yesterday | Entrepreneur Magazine

    ... who you're publishing for as long as your blog gets updated frequently. An example of a generic blog is Johnson and Johnson . This model is an ambitious one for a small company. If Jane decides to adopt this approach, she needs three websites, one ...

    Comment?

  4. How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge FundsRead the original story w/Photo

    Yesterday | Benzinga

    The tumble was set in motion after Express Scripts Holding Company , the largest pharmacy benefits manager in the United States, selected AbbVie Inc over Gilead and Johnson & Johnson for its Hepatitis C drug. Below is a closer look at a few hedge funds that could be taking a big hit as Gilead and peers fall this week, using third quarter 13F filings.

    Comment?

  5. Comprehensive analysis of the global composites in orthopedic marketRead the original story w/Photo

    Yesterday | Medical News

    Composites in global orthopedic industry are expected to grow at an average rate of 8.1%. The US has highest consumption in terms of value and volume.

    Comment?

  6. 4 Reasons I'm Adding Gilead To My Healthcare HoldingsRead the original story w/Photo

    Yesterday | Seeking Alpha

    After minimizing my risk in the healthcare space, I am buying what many now consider to be a high risk stock in GILD. Despite GILD's big stock decline on Monday, there are reasons to believe the stock reaction did not warrant the news.

    Comment?

  7. Talcum Powder Attorneys Explain Class Action LawsuitsRead the original story w/Photo

    Yesterday | PRWeb

    The lawyers handling talcum powder cancer lawsuits at the Onder Law Firm expand their coverage of talcum powder class action lawsuits to distinguish between ovarian cancer claims and economic claims; new information is available at the firm's website, TalcumPowderOvarianCancerCenter.com. We believe women and the family members of women who have suffered from ovarian cancer may be entitled to real and meaningful compensation.

    Comment?

  8. We Made a List and Checked It Twice: BioSpace??'s Naughty and NiceRead the original story w/Photo

    Yesterday | BioSpace

    December 24, 2014 By Riley McDermid and Jessica Wilson , BioSpace.com Breaking News As we round out the year 2014, BioSpace has been combing through our archives for some examples of truly outstanding behavior in biotech-either because it was so heavenly, or because it was so heinous. Sadly, we had a much harder time finding nominees for our "nice" category.

    Comment?

  9. Dow Jones storms past 18,000 for first time as U.S. economy grows at fastest pace in 11 yearsRead the original story w/Photo

    Tuesday | Canada.com

    The best GDP reading since 2003 this morning added more fuel to fire under U.S. stocks, which have now climbed 1,000 since July. The Dow Jones Industrial Average smashed through a new record high of above 18,000 Tuesday as strong U.S. economic data and dropping oil prices fuelled investor optimism for blue-chip companies.

    Comment?

  10. AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express ScriptsRead the original story w/Photo

    Tuesday | Seeking Alpha

    Gilead Sciences' stock has been hit hard by the exclusive distribution deal between AbbVie and Express Scripts to distribute the Hepatitis C drug, Viekira Pak. Analyst reactions have been quick to cut target pricing and predict a 15% to 25% negative future impact on Gilead's share value.

    Comment?

  11. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015Read the original story w/Photo

    Tuesday | GuruFocus.com

    Now that the year is coming to an end, what stocks should investors be on the lookout for in the first quarter of the New Year? To answer this question, William Blair analyst Y. Katherine Xu named 5 Biotechnology stocks to watch in the first quarter of 2015. Medivation is best known for developing therapies to treat serious diseases.

    Comment?

  12. Johnson & Johnson (JNJ) and the $1 Million Bearish BetRead the original story

    Tuesday | SchaeffersResearch.com

    Express Scripts Holding Company's exclusive pact with AbbVie Inc continues to create headwinds throughout the pharmaceutical sector. In the equity's options pits, put volume has popped to seven times what's typically seen at this point in the day, with one speculator betting big on an extended decline for JNJ over the next several weeks.

    Comment?

  13. RPT - EXCLUSIVE-Express Scripts presses for more drug savings with coverage listRead the original story w/Photo

    Tuesday | AlertNet

    Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's rival treatments after trying for nearly a year to win a deeper discount.

    Comment?

  14. Peter Lynch On Dividend Growth InvestingRead the original story w/Photo

    Tuesday | Seeking Alpha

    During his tenure he owned thousands of companies and focused on everything from special situations and high-growth, to treasury bonds and cyclicals. If there were an investing hall of fame, it'd be a reasonable bet that Peter Lynch would be in it.

    Comment?

  15. Trial confirms Ebola vaccine candidate safe and equally immunogenic in AfricaRead the original story w/Photo

    Tuesday | PhysOrg Weblog

    A scanning electron micrograph of Ebola virus budding from a cell . Credit: NIAID Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year.

    Comment?

  16. Johnson & Johnson: Still A Great Income Stock, If A Bit ExpensiveRead the original story w/Photo

    Tuesday | Seeking Alpha

    Shares of consumer goods company Johnson and Johnson have risen impressively over the past three years. That strong performance has netted holders some of the biggest returns in the Dow over that timeframe, including dividends.

    Comment?

  17. Xarelto Suits Sent to LouisianaRead the original story w/Photo

    Monday | jdsupra.com

    Xarelto is a new generation anticoagulant in a class of drugs known as direct thrombin inhibitors. It is a blood thinner used to reduce the risk of blood clots and strokes.

    Comment?

  18. Exclusive: Express Scripts presses for more drug savings with coverage listRead the original story

    Monday | Reuters

    Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's rival treatments after trying for nearly a year to win a deeper discount.

    Comment?

  19. Ebola Vaccine Trial in Africa May Support More Potent VersionRead the original story

    Monday | Bloomberg

    An experimental Ebola vaccine showed it was safe and generated an immune response in healthy Ugandan adults in a clinical trial that bodes well for a more potent version undergoing testing. "This is the first study to show comparable safety and protection of an experimental Ebola vaccine in an African population," said Julie Ledgerwood , lead author of results published today in the Lancet journal.

    Comment?

  20. The Real Values Of Dividend Growth InvestingRead the original story w/Photo

    Monday | Seeking Alpha

    The ability to custom-tailor cash flow as well as analyze cash extraction potential are two benefits of equity-income investing. There is a belief among many that total return is the consummate measure of equity investment success .

    Comment?